152 related articles for article (PubMed ID: 33904990)
1. Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow.
Shenoy-Bhangle AS; Tsai LL; Masciocchi M; Arora SS; Kielar AZ
Abdom Radiol (NY); 2021 Aug; 46(8):3558-3564. PubMed ID: 33904990
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
3. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
6. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
7. Imaging diagnosis of hepatocellular carcinoma: LI-RADS.
Cunha GM; Sirlin CB; Fowler KJ
Chin Clin Oncol; 2021 Feb; 10(1):3. PubMed ID: 32527115
[TBL] [Abstract][Full Text] [Related]
8. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
[TBL] [Abstract][Full Text] [Related]
9. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma.
Youn SY; Kim B; Kim DH; Choi HJ; Sung PS; Choi JI
Eur Radiol; 2022 Sep; 32(9):6270-6280. PubMed ID: 35348864
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
12. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
13. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
14. Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations.
Mitchell DG; Bashir MR; Sirlin CB
Abdom Radiol (NY); 2018 Jan; 43(1):143-148. PubMed ID: 28779335
[TBL] [Abstract][Full Text] [Related]
15. Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication.
Corwin MT; Lee AY; Fananapazir G; Loehfelm TW; Sarkar S; Sirlin CB
AJR Am J Roentgenol; 2018 Jan; 210(1):85-90. PubMed ID: 29023148
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
18. LI-RADS: Past, Present, and Future, From the
Marks RM; Masch WR; Chernyak V
AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
[TBL] [Abstract][Full Text] [Related]
19. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
[TBL] [Abstract][Full Text] [Related]
20. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters.
Centonze L; Di Sandro S; Lauterio A; De Carlis R; Sgrazzutti C; Ciulli C; Vella I; Vicentin I; Incarbone N; Bagnardi V; Vanzulli A; De Carlis L
Transpl Int; 2021 Sep; 34(9):1712-1721. PubMed ID: 34448275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]